Research groups
Rachel Upthegrove
MBE, MBBS, FRCPsych, PhD
Professor of Psychiatry, Director NIHR Oxford Health Biomedical Research Centre
- Chair NIHR Mental Health Translational Research Collaboration (MH-TRC)
- Co-lead Early Psychosis, Molecular Targets BRC Theme
- Professor of Psychiatry and Youth Mental Health, Institute for Mental Health, University of Birmingham
- Honorary Consultant Psychiatrist, Early Intervention in Psychosis
- Honorary General Secretary, British Association for Psychopharmacology
Early Psychosis, Severe Mental Illness, Immunopsychiatry, Multimorbidity
Rachel trained in Medicine at the Royal Free Hospital, University of London and completed her PhD at the University of Birmingham, investigating depression and suicidality in first episode psychosis. Her research focuses on the identification of novel treatments for early stages of severe mental illness with focus on co-morbidity.
She leads the Psychosis Immune Mechanism Stratified Medicine Study (PIMS), a collaborative multi-stage project investigating inflammatory mechanisms and phenotypic profile of psychosis. PIMS is currently completing a targeted trial of Tocilizumab in patients with early psychosis and evidence of immune activation.
Rachel is chief investigator and co-investigator on a number of NIHR funded trials for repurposed and targeted treatments, including the NIHR HTA ADEPP study (Antidepressants for the prevention of depression following first episode psychosis).
Her translational research includes NIHR funded Early Psychosis Informatics into Care (EPICare), a collaborative project developing a national digital registry and clinical decision support system for patients and clinicians in early intervention services.
Recent publications
From Snapshots to Stable Outcomes: Resting-State Functional Magnetic Resonance Imaging-Based Prognosis of Functioning in Patients With Psychosis Risk or Recent-Onset Depression.
Journal article
Buciuman M-O. et al, (2026), Biol Psychiatry, 99, 692 - 705
Cardiometabolic prediction models for young people with psychosis spectrum disorders in the UK (PsyMetRiC 2.0): a retrospective, multicohort clinical prediction model study.
Journal article
Perry BI. et al, (2026), Lancet Psychiatry, 13, 291 - 303
Evidence of phenotypes indexing cognitive resilience and vulnerability in the early course of mood and psychosis spectrum illness; mapping the latent structure, characteristics, and longitudinal stability of cognitive heterogeneity.
Journal article
Van Rheenen TE. et al, (2026), Eur Neuropsychopharmacol, 107
Inflammatory markers (IL-6 and CRP) in childhood and their association with brain structure and psychotic experiences in adulthood.
Journal article
Merritt K. et al, (2026), Brain Behav Immun, 133
Brain texture alterations predict subtle visual perceptual dysfunctions in recent onset psychosis and clinical high-risk state.
Journal article
Lencer R. et al, (2026), Transl Psychiatry, 16
Women at the heart of mental science: commentary, Pinto da Costa et al.
Journal article
Pinto da Costa M. et al, (2026), Br J Psychiatry, 1 - 3
Treatment resistance in first-episode psychosis.
Journal article
McCutcheon RA. et al, (2026), World Psychiatry, 25, 50 - 51
Multivariate Brain-Blood Signatures in Early-Stage Depression and Psychosis.
Journal article
Popovic D. et al, (2026), JAMA Psychiatry, 83, 172 - 184
Antipsychotic Potential of Low-Dose Methotrexate: A Retrospective Cohort Study Based on Electronic Health Records
Preprint
Corsi-Zuelli F. et al, (2026)
Non-pharmacologicaL InterVEntions for Antipsychotic-Induced Weight Gain (RESOLVE) in People Living With Severe Mental Illness: A Realist Synthesis.
Journal article
MacPhee M. et al, (2025), Obes Rev, 26
